The efficacy of cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy (ET) for advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer has sparked intense debate as an upfront local treatment [8,9,10,11]. This evidence concerns the gene NR4A1 and breast carcinoma.